PolymarketGeslotenBeschikbaarheid controlerenGeen KYC2% kostenGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdDeze markt is beslist: Yes
Afgewikkeld: 28 jun 2026, 23:21
Door provider geverifieerde afwikkeling
CoinRithm heeft provider-onderbouwd bewijs voor de winnaar en afwikkelingstijd van deze markt.
Winnende Uitkomst
Yes
Op 7 dagen afstand
—
Op 24 uur afstand
—
Huidige impliciete kans
Ja 100%+0.0pt
Marktkwaliteit
≤49 / 100
Lage kwaliteit24u volume
€ 4,8K
Liquiditeit
—
Liquiditeit onbekendBied / Laat
99.9% / 100.0%
Spread
0.1 pt
Strakke spread7d wijziging
+26.9 pts
Marktdata
Bijgewerkt 64 dagen geleden
Verouderd4 jun 26, 19:5430 jun 26, 0:00
Waarschijnlijkheidstijdlijn
No0%
Yes100%
100%
0%
Regels
As of market creation, the FDA's expected decision date for the specified application is June 30, 2026.
- This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Viridian Therapeutics's Veligrotug as a treatment for thyroid eye disease by July 14, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
